• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

条件性小鼠异位骨化的可靠诱导方法。

Methods for the reliable induction of heterotopic ossification in the conditional mouse.

机构信息

University of Michigan School of Dentistry, Ann Arbor, MI.

Vanderbilt Center for Bone Biology.

出版信息

J Musculoskelet Neuronal Interact. 2020 Mar 3;20(1):149-159.

PMID:32131380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7104591/
Abstract

OBJECTIVES

Conditional () mice have previously been used as a model of heterotopic ossification (HO). However, HO formation in this model can be highly variable, and it is unclear which methods reliably induce HO. Hence, these studies report validated methods for reproducibly inducing HO in mice.

METHODS

Varying doses of Adex-cre and cardiotoxin (CTX) were injected into the calf muscles of 9, 14, or 28-day-old or mice. HO was measured by planar radiography or microCT at 14-28 days post-injury.

RESULTS

In 9-day-old or mice, single injections of 10 PFU Adex-cre and 0.3 μg of CTX were sufficient to induce extensive HO within 14 days post-injury. In 28-day-old mice, the doses were increased to 5 x 10 PFU Adex-cre and 3.0 μg of CTX to achieve similar consistency, but at a slower rate versus younger mice. Using a crush injury, instead of CTX, also provided consistent induction of HO. Finally, the Type 1 BMPR inhibitor, DMH1, significantly reduced HO formation in 28-day-old mice.

CONCLUSIONS

These data illustrate multiple methods for reliable induction of localized HO in the mouse that can serve as a starting point for new laboratories utilizing this model.

摘要

目的

条件性 ()小鼠先前被用作异位骨化 (HO) 的模型。然而,该模型中的 HO 形成具有高度可变性,并且不清楚哪种方法能够可靠地诱导 HO。因此,这些研究报告了在 小鼠中可靠诱导 HO 的验证方法。

方法

在 9、14 或 28 日龄的 或 小鼠的小腿肌肉中注射不同剂量的 Adex-cre 和心脏毒素 (CTX)。在损伤后 14-28 天通过平面射线照相术或 microCT 测量 HO。

结果

在 9 日龄的 或 小鼠中,单次注射 10 PFU Adex-cre 和 0.3 μg CTX 足以在损伤后 14 天内诱导广泛的 HO。在 28 日龄的小鼠中,剂量增加到 5×10 PFU Adex-cre 和 3.0 μg CTX 以达到类似的一致性,但速度比年轻小鼠慢。使用挤压伤而不是 CTX 也可以提供一致的 HO 诱导。最后,I 型 BMPR 抑制剂 DMH1 显著减少了 28 日龄 小鼠中的 HO 形成。

结论

这些数据说明了在小鼠中可靠诱导局部 HO 的多种方法,可为利用该模型的新实验室提供起点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/c7396de811af/JMNI-20-149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/4d246f90e9ae/JMNI-20-149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/9b75297110e5/JMNI-20-149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/55e0f8a502fe/JMNI-20-149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/317ab788a42c/JMNI-20-149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/6f3096c4b83f/JMNI-20-149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/e17a1d070f0e/JMNI-20-149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/933aa1e5ff41/JMNI-20-149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/c7396de811af/JMNI-20-149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/4d246f90e9ae/JMNI-20-149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/9b75297110e5/JMNI-20-149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/55e0f8a502fe/JMNI-20-149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/317ab788a42c/JMNI-20-149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/6f3096c4b83f/JMNI-20-149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/e17a1d070f0e/JMNI-20-149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/933aa1e5ff41/JMNI-20-149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/7104591/c7396de811af/JMNI-20-149-g008.jpg

相似文献

1
Methods for the reliable induction of heterotopic ossification in the conditional mouse.条件性小鼠异位骨化的可靠诱导方法。
J Musculoskelet Neuronal Interact. 2020 Mar 3;20(1):149-159.
2
Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良小鼠模型中的异位骨化
Methods Mol Biol. 2019;1891:247-255. doi: 10.1007/978-1-4939-8904-1_18.
3
BMP type I receptor inhibition reduces heterotopic [corrected] ossification.骨形态发生蛋白I型受体抑制可减少异位骨化。 (注:原文中“heterotopic [corrected] ossification”可能有误,推测应为“heterotopic ossification”,即异位骨化,这里按照推测后的正确内容进行了翻译)
Nat Med. 2008 Dec;14(12):1363-9. doi: 10.1038/nm.1888. Epub 2008 Nov 30.
4
Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Mouse Model of Fibrodysplasia Ossificans Progressiva.破骨细胞和巨噬细胞耗竭可损害 Acvr1 小鼠纤维性骨发育不良进展性异位骨化模型中的异位骨化。
J Bone Miner Res. 2018 Feb;33(2):269-282. doi: 10.1002/jbmr.3304. Epub 2018 Jan 3.
5
Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.进行性骨化性纤维发育不良:ACVR1 中独特的错义突变(c.974G>C,p.G325A)导致中年发病的异位骨化。
J Bone Miner Res. 2012 Mar;27(3):729-37. doi: 10.1002/jbmr.1473.
6
BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints.由组成型激活的激活素1型受体(ACVR1)介导的骨形态发生蛋白(BMP)信号传导导致异位骨形成,局限于远端关节。
Dev Biol. 2015 Apr 15;400(2):202-9. doi: 10.1016/j.ydbio.2015.02.011. Epub 2015 Feb 23.
7
Scleraxis-Lineage Cells Contribute to Ectopic Bone Formation in Muscle and Tendon.硬骨素谱系细胞促成肌肉和肌腱中的异位骨形成。
Stem Cells. 2017 Mar;35(3):705-710. doi: 10.1002/stem.2515. Epub 2016 Nov 8.
8
The development of a mouse model to investigate the formation of heterotopic ossification.用于研究异位骨化形成的小鼠模型的建立。
J Orthop Surg (Hong Kong). 2023 Jan-Apr;31(1):10225536231163466. doi: 10.1177/10225536231163466.
9
Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.帕罗维罗汀可抑制携带人类ACVR1(R206H)突变的进行性骨化性纤维发育不良(FOP)小鼠的异位骨化,并维持肢体活动能力和生长。
J Bone Miner Res. 2016 Sep;31(9):1666-75. doi: 10.1002/jbmr.2820. Epub 2016 Mar 12.
10
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.ACVR1基因R206H受体突变通过赋予对激活素A的反应性导致进行性骨化性纤维发育不良。
Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.

引用本文的文献

1
A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice.一种新型BMP 1型受体激酶抑制剂,用于安全有效的口服治疗,以预防小鼠基因诱导的异位骨化。
Bone. 2025 Oct;199:117565. doi: 10.1016/j.bone.2025.117565. Epub 2025 Jun 18.
2
Discoidin domain receptor 2 is an important modulator of BMP signaling during heterotopic bone formation.盘状结构域受体2是异位骨形成过程中骨形态发生蛋白信号的重要调节因子。
Bone Res. 2025 Jan 2;13(1):7. doi: 10.1038/s41413-024-00391-z.
3
Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology.

本文引用的文献

1
Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.激活素依赖性信号在纤维/脂肪祖细胞中引起进行性骨化性纤维发育不良。
Nat Commun. 2018 Feb 2;9(1):471. doi: 10.1038/s41467-018-02872-2.
2
The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.纤维性骨发育不良性骨生成过度中的异位骨形成是激活素 A 依赖性的。
J Bone Miner Res. 2017 Dec;32(12):2489-2499. doi: 10.1002/jbmr.3235. Epub 2017 Sep 22.
3
Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
采用 DNA 编码化学技术发现高效的、ALK2/ALK1 选择性的激酶抑制剂。
Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2413108121. doi: 10.1073/pnas.2413108121. Epub 2024 Nov 14.
4
MyD88 Is Not Required for Muscle Injury-Induced Endochondral Heterotopic Ossification in a Mouse Model of Fibrodysplasia Ossificans Progressiva.在进行性骨化性纤维发育不良小鼠模型中,肌肉损伤诱导的软骨内异位骨化不需要MyD88。
Biomedicines. 2021 Jun 1;9(6):630. doi: 10.3390/biomedicines9060630.
5
Generation of a new mouse line with conditionally activated signaling through the BMP receptor, ACVR1: A tool to characterize pleiotropic roles of BMP functions.通过 BMP 受体 ACVR1 条件性激活信号生成新的小鼠品系:一种用于表征 BMP 功能多效性作用的工具。
Genesis. 2021 Jun;59(5-6):e23419. doi: 10.1002/dvg.23419. Epub 2021 Apr 14.
6
Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良中的心肺和神经功能障碍
Biomedicines. 2021 Feb 5;9(2):155. doi: 10.3390/biomedicines9020155.
7
Genetic and Acquired Heterotopic Ossification: A Translational Tale of Mice and Men.遗传与后天性异位骨化:小鼠与人类的转化故事
Biomedicines. 2020 Dec 14;8(12):611. doi: 10.3390/biomedicines8120611.
激活素A增强mTOR信号传导,以促进进行性骨化性纤维发育不良中的异常软骨形成。
J Clin Invest. 2017 Sep 1;127(9):3339-3352. doi: 10.1172/JCI93521. Epub 2017 Jul 31.
4
Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.对多种骨形态发生蛋白受体的靶向作用可预防创伤诱导的异位骨化。
Mol Ther. 2017 Aug 2;25(8):1974-1987. doi: 10.1016/j.ymthe.2017.01.008. Epub 2017 Jul 15.
5
The traumatic bone: trauma-induced heterotopic ossification.创伤性骨:创伤诱导的异位骨化。
Transl Res. 2017 Aug;186:95-111. doi: 10.1016/j.trsl.2017.06.004. Epub 2017 Jun 15.
6
The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.在进行性骨化性纤维发育不良中,激活素 A 在异位骨形成中的必然作用。
Bone. 2018 Apr;109:210-217. doi: 10.1016/j.bone.2017.06.011. Epub 2017 Jun 16.
7
Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)患者的纵向报告移动性评估。
Bone. 2018 Apr;109:158-161. doi: 10.1016/j.bone.2017.06.005. Epub 2017 Jun 6.
8
Dynamics of MMP‑9, MMP‑2 and TIMP‑1 in a rat model of brain injury combined with traumatic heterotopic ossification.脑损伤合并创伤性异位骨化大鼠模型中 MMP-9、MMP-2 和 TIMP-1 的动态变化。
Mol Med Rep. 2017 Apr;15(4):2129-2135. doi: 10.3892/mmr.2017.6275. Epub 2017 Mar 1.
9
Establishment of heterotopic ossification via sharp instrument injury in rats.通过锐器损伤在大鼠中建立异位骨化。
J Musculoskelet Neuronal Interact. 2017 Mar 1;17(1):456-460.
10
Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良中异位骨的X线评估模拟方法
Acad Radiol. 2017 Mar;24(3):321-327. doi: 10.1016/j.acra.2016.10.010. Epub 2016 Dec 15.